LIMNW
Liminatus Pharma, Inc. Warrants
NASDAQ · Healthcare · Biotechnology · US
$0.06
+0.00%Price chart
Jul 21Jul 24Aug 3Aug 10Aug 13Aug 19Aug 26Aug 31
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.0x
Market Cap
$1.49M
MomentumView details →
1D Return
+0.00%
YTD Return
+57.71%
RSI (14)
49.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.0x
Market Cap
$1.49M
RSI (14)
49.9
MomentumView details →
1D Return
+0.00%
YTD Return
+57.71%
SummaryUpdated Jun 1, 2026
Liminatus Pharma, Inc. (NASDAQ:LIMNW) is a clinical-stage immuno-oncology biotechnology company founded and based in La Palma, California. The company went public in April 2025 and focuses on developing novel cancer therapies that harness the body's immune system to fight cancer. As a pre-revenue biotechnology company, Liminatus is in the early stages of drug development, working to advance its therapeutic candidates through clinical trials with the ultimate goal of bringing new cancer treatments to market.
Similar companies
Latest newsMore news →
Liminatus Pharma, Inc. announced a 1-for-50 reverse stock split of its common stock, approved by its board and stockholders at the 2026 Annual Meeting held on August 3, 2026.17d agoLiminatus Pharma, Inc. received a notice from NASDAQ on 2026-08-12 that it is not in compliance with Listing Rule 5550(a)(2) regarding minimum bid price, and plans to implement a 1-for-50 reverse stock split.18d agoLiminatus Pharma, Inc. issued 11,188,729 shares of common stock and 158,881.1271 shares of newly designated Series A Non-Voting Convertible Preferred Stock in connection with its merger, exempt from registration under Section 4(a)(2) of the Securities Act of 1933.61d ago